Publications by authors named "M C Thebault"

Warm autoimmune hemolytic anemia (wAIHA) is a rare acquired autoimmune disease mediated by antibodies targeting red blood cells. The involvement of CD4 T-helper cells has been scarcely explored, with most findings extrapolated from animal models. Here, we performed quantification of both effector T lymphocytes (Teff) and regulatory T cells (Treg), associated with functional and transcriptomic analyses of Treg in human wAIHA.

View Article and Find Full Text PDF
Article Synopsis
  • Recently developed human monocyte-derived suppressor cells (HuMoSC), specifically CD33+ subpopulation, show potential in reducing graft-versus-host disease (GvHD) severity in mice.
  • Researchers found that the supernatant from CD14+HuMoSC significantly inhibits T cell proliferation and cytotoxicity, effectively reducing GvHD in NSG mice.
  • The CD14+HuMoSC supernatant can be produced with good manufacturing practices and may serve as a complementary treatment alongside existing immunosuppressive drugs for GvHD prevention.
View Article and Find Full Text PDF

Objectives: To study the percentage, suppressive function and plasticity of Treg in giant cell arteritis (GCA), and the effects of glucocorticoids and tocilizumab.

Methods: Blood samples were obtained from 40 controls and 43 GCA patients at baseline and after treatment with glucocorticoids + IV tocilizumab ( = 20) or glucocorticoids ( = 23). Treg percentage and phenotype were assessed by flow cytometry.

View Article and Find Full Text PDF

This study aimed to assess the implication of mucosal-associated invariant T (MAIT) cells in GCA. Blood samples were obtained from 34 GCA patients (before and after 3 months of treatment with glucocorticoids (GC) alone) and compared with 20 controls aged >50 years. MAIT cells, defined by a CD3CD4TCRγδTCRVα7.

View Article and Find Full Text PDF

Background: Immunosuppressive cell-based therapy is a recent strategy for controlling Graft--Host Disease (GvHD). Such cells ought to maintain their suppressive function in inflammatory conditions and in the presence of immunosuppressive agents currently used in allogeneic hematopoietic cell transplantation (allo-HCT). Moreover, these therapies should not diminish the benefits of allo-HCT, the Graft--Leukemia (GvL) effect.

View Article and Find Full Text PDF